PROTOKOLwiki
COMPOUNDS / PEPTIDE / TB-500
PEPTIDE

TB-500

HIGH RISK
BEST FOR:Recovery●●●●●●○○○○6/10
TB-500 · THYMOSIN BETA-4 FRAGMENT · AC-LKKTETQ · TΒ4 FRAGMENT · THYMOSIN Β4 ACTIVE SITE · N-ACETYL-LKKTETQ
PeptideTissue RepairWound HealingRecoveryWADA BannedGray Market

Synthetic thymosin beta-4 fragment promoted for tissue repair and wound healing, with evidence limited to preclinical models.

ROUTE / DOSAGE
LOW2mg
STANDARD2-5mg
HIGH10mg
Note: Typically administered 2x/week for 4-6 weeks loading phase, then 1x/month maintenance. No human clinical dosing established.
CYCLE
4 weeks continuous daily administration in rat studies no human cycle data
BIOAVAILABILITY
~80% subq ~80% im
ACTIVE DURATION
2-4 weeks per cycle (subjective)
STORAGE
Lyophilized powder: room temperature or refrigerated dry away from light. Reconstituted solution: refrigerate at 2-8°C use within 30 days
HALF-LIFE
Not established in humans metabolite Ac-LKK detected up to 72 hr in rats (plasma)
DURATION BREAKDOWN
Total2-4 weeks per cycle
Onset3-7 days
Come up1-2 weeks
Peak2-4 weeks
Offset1-2 weeks
After effectsweeks-months
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
6 documented
Promotes angiogenesis and endothelial cell differentiation
Enhances tissue repair and wound healing
Improves collagen deposition and matrix organization
Reduces inflammation
Facilitates keratinocyte migration
Increases maximum load to failure in tendon repair
§ 02 — RISKS
No human clinical trials establishing safety or efficacy
Banned substance in competitive sports (WADA)
Sold through unregulated gray market without quality control oversight
Unknown optimal dosing, frequency, and treatment duration in humans
Potential for serious harm with unknown long-term safety profile
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

Preclinical rat studies demonstrate improved Achilles tendon healing with significantly increased maximum load to failure and improved histopathological parameters at 60 µg/kg/day intraperitoneally over four weeks. In vitro studies suggest wound-healing activity may be attributable to the metabolite Ac-LKKTE rather than the parent compound. However, human orthopaedic data are entirely lacking, and TB-500 remains a banned substance in competitive sports. No clinical trials have established safety, efficacy, optimal dosing, or treatment duration in humans. The compound is distributed through unregulated gray market channels without regulatory oversight.

§ 06 — SOURCES
[1]
PubMed PMID 41490200
pubmed.ncbi.nlm.nih.gov ↗
[2]
PubMed PMID 41476424
pubmed.ncbi.nlm.nih.gov ↗
[3]
PubMed PMID 41966639
pubmed.ncbi.nlm.nih.gov ↗
[4]
PubMed PMID 38382158
pubmed.ncbi.nlm.nih.gov ↗
[5]
PubMed PMID 42542926
pubmed.ncbi.nlm.nih.gov ↗
[6]
PubMed PMID 23084823
pubmed.ncbi.nlm.nih.gov ↗
[7]
PubMed PMID 28887173
pubmed.ncbi.nlm.nih.gov ↗
[8]
PubMed PMID 42021992
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT